Navigation Links
PTC Therapeutics Announces Data Supporting Cough Frequency as a New Outcome Measure in Evaluating Treatments for Cystic Fibrosis
Date:5/21/2008

. In Phase 1 clinical trials, PTC124 was generally well tolerated, achieved target plasma concentrations that have been associated with activity in preclinical models and did not induce ribosomal read through of normal stop codons. PTC124 has demonstrated pharmacodynamic proof of concept in Phase 2a clinical trials in nonsense-mutation-mediated Duchenne muscular dystrophy (DMD) and cystic fibrosis (CF).

About PTC Therapeutics Inc.

PTC is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary, small-molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are of central importance to proper cellular function. PTC's internally-discovered pipeline addresses multiple therapeutic areas, including genetic disorders, oncology and infectious diseases. In addition, PTC has developed proprietary technologies and extensive knowledge of post-transcriptional control processes that it applies in its drug discovery and development activities, including the Gene Expression Modulation by Small-molecules (GEMS) technology platform, which has been the basis for collaborations with leading pharmaceutical and biotechnology companies such as Pfizer, Celgene, CV Therapeutics and Schering-Plough. For more information, visit the company's website, http://www.ptcbio.com.


'/>"/>
SOURCE PTC Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease
2. PacificGMP Completes GMP Product Fill for Trius Therapeutics
3. Velcura Therapeutics, Inc. Reports Successful Phase 1 Clinical Trial of Novel Bone Disease Therapy
4. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
5. Cara Therapeutics Initiates Phase 1 Clinical Trial of Novel Analgesic, CR845
6. PTC Therapeutics Announces Initiation of Phase 2b Registration-Directed Clinical Trial of PTC124 in Duchenne/Becker Muscular Dystrophy
7. Halozyme Therapeutics Presents Findings on Combinations of rHuPH20 Enzyme With Bisphosphonates at the American Association for Cancer Research Conference
8. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Echo Therapeutics Announces Positive Results with the Prelude(TM) SkinPrep System, the Next-Generation Skin Permeation Medium for its Symphony(TM) Transdermal Continuous Glucose Monitoring System
11. Recent siRNA Research Publications Support Silence Therapeutics Combined Development Approach
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... , June 30, 2015 Pulse Light ... a survey to Rosacea sufferers as part of their ongoing ... Rosacea sufferers found effective for their Rosacea. The survey participants ... comprised 47% men and 53% women. The results ... participants did not consider or attempt to visit their GP ...
(Date:6/30/2015)... , June 30, 2015  Ardelyx, Inc. (NASDAQ: ... cardio-renal, gastrointestinal and metabolic diseases, today announced that the ... 14, 2015, from 8:00 a.m.- 1:00 pm EDT in ... The Ardelyx senior management team will present an ... compound, tenapanor, which has completed Phase 2b clinical trials ...
(Date:6/30/2015)... , BERKELEY, Kalifornien, und KOPENHAGEN, Dänemark, ... Biologics, Inc. , ein Weltmarktführer der klinischen ... anderen therapeutischen Proteinen, gab heute bekannt, dass ... der Produktionskapazität den Ausbau der nordamerikanischen Produktionsanlage ... mit der Ergänzung  einer Einweg-Anlage Bioreactor 6Pack™ ...
Breaking Medicine Technology:84% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 284% of Rosacea Sufferers Say NHS Treatments Were "Ineffective" New Survey Reveals 3Ardelyx to Host Inaugural R&D Investor Day in New York City on July 14, 2015 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3
... Mass., Oct. 26, 2011 Idenix Pharmaceuticals, Inc. (NASDAQ: ... financial results for the third quarter of 2011 on Wednesday, ... Idenix management will host a conference call at 4:30 p.m. ... financial results for the third quarter of 2011 and provide ...
... MECHANICSBURG, Pa., Oct. 26, 2011 One out of three ... according to an Opinion Research/Select Medical telephone poll. Against that ... a statement today reminding the American public that influenza season ... chronic lung disease such as asthma or COPD (Chronic Obstructive ...
Cached Medicine Technology:Idenix to Host Conference Call Discussing Third Quarter and Nine Month 2011 Financial Results and Announces Presentations at the American Association for the Study of Liver Diseases Meeting (AASLD) 2Poll: One Out of Three U.S. Adults Not Planning to Get Flu Shot This Year 2
(Date:6/30/2015)... ... June 30, 2015 , ... ... Rehab”. The video focuses on the rehab center’s patients and their experiences at ... the best quality of services available. Each patient attests to the high rating, ...
(Date:6/30/2015)... ... June 30, 2015 , ... Broadway by the Sea posted its ... and family member testimonials. Medicare rated the care center as a five-star location based ... video to give future patients a firsthand look at the facility’s satisfied residents. ...
(Date:6/30/2015)... ... June 30, 2015 , ... The progress of ... multidistrict litigation now underway in the U.S. District Court, Eastern District of Louisiana, ... to the Court’s calendar, that conference has now been scheduled for July 9th, ...
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... ... community. , Eleven physicians from Allied’s Fullerton division volunteered to help provide free ... Super Surgery Saturday, March 21, at St. Jude Medical Center. , The ...
(Date:6/30/2015)... ... June 30, 2015 , ... Red Hot & Blue Restaurants, ... online poll at http://scoutology.com/novaburgerwars and was selected as “Best BBQ” in a ... 2015. , Red Hot & Blue President Randy McCann said, “Everyone knows Red Hot ...
Breaking Medicine News(10 mins):Health News:Patients of University Post-Acute Rehab Support Five-Star Rating in New Video 2Health News:Broadway by the Sea Video Promotes Top Quality Service 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 2Health News:Progress of Federal Xarelto Lawsuits Pending in Multidistrict Litigation to Be Discussed During July 9th Status Conference 3Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 2Health News:Allied Anesthesia Physicians Volunteer to Help Orange County’s Uninsured During Annual Super Surgery Saturday 3Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 2Health News:Red Hot & Blue BBQ Restaurants Voted "Best Burger" in Virginia and "Best Barbecue" in Texas 3
... Nov. 6, 2008 Advanced age and race are ... dies or suffers a stroke after carotid-artery surgery, a ... found. , "This study identified 11 readily available, ... surgeons and anesthesiologists better weigh the risks and benefits ...
... The Content of His Character ... Statement of Lorraine Cole, Ph.D., YWCA ... ... had the privilege of,conducting an oral history interview with Dr. Dorothy Height, who ... her move to New York to take that position, she served as the,Executive ...
... Percent Increase in IVUS System Sales, SAN DIEGO, ... a leader in the development, manufacturing and sales of,products ... artery,disease, today reported that revenues for the third quarter ... quarter of 2007., For the quarter ended September ...
... Share of $0.32 and Contract Value of $230.6 million; Announces New Program ... ... Board Company,(Nasdaq: ABCO ) today announced financial results for the second quarter ... $57.6 million, from $54.0 million in the second quarter of fiscal 2008.,Net income ...
... Ind., Nov. 5 Conseco, Inc. (NYSE:,CNO) today ... "We are pleased,with the performance of our core ... "with income before net realized investment losses,corporate interest ... the,favorable end of the estimated ranges we provided ...
... Nov. 5 The American Dental,Association (ADA) continues to ... the 2008 Golden Apple Awards. The Golden Apple,Awards program, ... society activities and excellence in leadership., The 2008 ... of the,year to the following societies:, -- ...
Cached Medicine News:Health News:Age, race are among factors that influence carotid-surgery success 2Health News:YWCA USA Recognizes Historic Election Milestone 2Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 2Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 3Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 4Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 5Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 6Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 7Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 8Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 9Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 10Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 11Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 12Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 13Health News:Volcano Reports 40 Percent Growth in Quarterly Revenues 14Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 2Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 3Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 4Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 5Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 6Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 7Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 8Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 9Health News:The Advisory Board Company Reports Fiscal Year 2009 Second Quarter Results 10Health News:Conseco Reports Third Quarter Results 2Health News:Conseco Reports Third Quarter Results 3Health News:Conseco Reports Third Quarter Results 4Health News:Conseco Reports Third Quarter Results 5Health News:Conseco Reports Third Quarter Results 6Health News:Conseco Reports Third Quarter Results 7Health News:Conseco Reports Third Quarter Results 8Health News:Conseco Reports Third Quarter Results 9Health News:Conseco Reports Third Quarter Results 10Health News:Conseco Reports Third Quarter Results 11Health News:Conseco Reports Third Quarter Results 12
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: